Advertisement

Internal and Emergency Medicine

, Volume 13, Issue 7, pp 1093–1096 | Cite as

Drug plasma level measurement in management of severe bleeding during direct oral anticoagulant treatment: case report and perspective

  • Dimitriy Arioli
  • Davide Donelli
  • Lorenzo Morini
  • Maria Cristina Leone
  • Emanuele Alberto Negri
CE - LETTER TO THE EDITOR

To the Editor,

The introduction of direct oral anticoagulants (DOACs) has changed the perspective about the patient’s needs in clinical practice. A complete understanding of their optimal management has yet to be achieved especially when dealing with critical patients.

Recently, a case has raised relevant questions about the correct management of patients presenting with severe bleeding during DOAC treatment. Starting from the learning points obtained from the case, we propose a possible algorithm to improve the care of patients presenting with severe bleeding during DOAC treatment. Before discussing, we report the case briefly.

A 65-year-old woman who was taking rivaroxaban 20 mg/day and acetylsalicylic acid 75 mg/day for ischaemic cardiomyopathy with persistent atrial fibrillation (AF) (CHA2DS2 VASC = 7), and recent history of ischemia in the upper limb, presented to the emergency department (ED) because of a syncope after 2 days of melaena. At admission, the patient (who suffered...

Keywords

Direct oral anticoagulants Thrombosis Haemostasis Drug plasma levels Severe bleeding Management 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Statements on human and animal rights

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Prisco D, Ageno W, Becattini C, D’Angelo A, Davì G, De Cristofaro R et al (2017) Italian intersociety consensus on DOAC use in internal medicine. Internal Emerg Med 12(3):387–406CrossRefGoogle Scholar
  2. 2.
    Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW et al (2017) 2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology task force on expert consensus decision pathways. J Am Coll Cardiol 70:3024–3067CrossRefGoogle Scholar
  3. 3.
    Levy JH, Ageno W, Chan NC, Crowther M, Verhamme P, Weitz JI (2016) When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost 14(3):623–627CrossRefGoogle Scholar
  4. 4.
    Tripodi A, Ageno W, Ciaccio M, Legnani C, Lippi G, Manotti C, Steffan A (2017) Position paper on laboratory testing for patients on direct oral anticoagulants. A consensus document from the SISET, FCSA, SIBioC and SIPMeL.Blood Transfusion = Trasfusione del sangue 1–9Google Scholar
  5. 5.
    Spyropoulos AC, Al-Badri A, Sherwood MW, Douketis JD (2016) Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery. J Thromb Haemost 14(5):875–885CrossRefGoogle Scholar
  6. 6.
    Heidbuchel H, Verhamme P, Alings M et al (2015) EP Europace 17(10):1467–1507CrossRefGoogle Scholar

Copyright information

© SIMI 2018

Authors and Affiliations

  1. 1.Medicina II Cardiovascolare, Department of Internal MedicineArcispedale Santa Maria Nuova - IRCCSReggio EmiliaItaly
  2. 2.Alta Intensità Medica, Department of Internal MedicineArcispedale Santa Maria Nuova - IRCCSReggio EmiliaItaly
  3. 3.Laureando CdLM Medicina e ChirurgiaUniversità di ParmaParmaItaly

Personalised recommendations